文献速递MDS 与骨髓增殖性肿瘤

生殖系JAK2 GGCC(46/1)单倍型与414例分子注释的原发性骨髓纤维化患者生存的关系

The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.
PubMed 文献 · Am J Hematol · 2018-12-05

该研究将原发性骨髓纤维化(PMF)患者增至414例,分析JAK2 46/1单倍型与生存的关系。单因素分析显示46/1阴性者总生存较差(HR 1.5,95%CI 1.1-1.9),在JAK2突变者中更明显(P<.001);多因素分析证实其独立预后贡献(P=.02;HR 1.4,95%CI 1.1-1.8)。在GIPSS模型中仍显著(P=.04),但在MIPSS70+版本2.0模型中不显著(P=.4)。

要点

  • 46/1单倍型阴性(nullizygosity)与PMF总生存较差相关(HR 1.5,95%CI 1.1-1.9)。
  • 该关联在JAK2突变者中更明显(P<.001),在CALR/MPL突变或三阴性者中不显著。
  • 多因素分析证实46/1阴性为独立预后因素(P=.02;HR 1.4,95%CI 1.1-1.8)。

核心结论

  • 本研究证实JAK2 GGCC(46/1)单倍型阴性(nullizygosity)与JAK2突变型PMF患者较差的总生存相关。

研究设计与样本

  • 研究纳入414例分子注释的原发性骨髓纤维化(PMF)患者(中位年龄63岁;63%为男性),分析JAK2 46/1单倍型与表型及预后的关系。

主要发现

  • JAK2 46/1单倍型见于69%的患者,其中25%为纯合、44%为杂合状态。
  • 46/1纯合/杂合/阴性患者的驱动突变频率分别为:JAK2 78%/60%/56%,1型样CALR 10%/20%/18%,2型样CALR 3%/2%/5%,MPL 4%/8%/7%,三阴性6%/10%/14%(P=.02)。
  • 单因素分析中,46/1阴性者总生存较差(HR 1.5,95%CI 1.1-1.9),在JAK2突变者中更明显(P<.001),而在CALR/MPL突变者(P=.48)或三阴性者(P=.27)中不显著。
  • 多因素分析(纳入核型、驱动突变状态和高分子风险突变)证实46/1阴性为独立预后因素(P=.02;HR 1.4,95%CI 1.1-1.8)。
  • 46/1阴性在GIPSS风险模型中仍显著(P=.04),但在整合遗传-临床的MIPSS70+版本2.0模型中不显著(P=.4);无白血病生存不受46/1单倍型影响(P=.6)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

JAK2 mutations in myeloproliferative neoplasms (MPNs) are associated with the germline GGCC (46/1) haplotype. In 2010, we reported an association between shortened survival in primary myelofibrosis (PMF) and nullizygosity for the JAK2 46/1 haplotype. In the current study, we have increased the number of informative cases from 130 to 414 (median age 63 years; 63% males), in order to revisit with the phenotypic and prognostic relevance of the JAK2 46/1 haplotype in PMF. JAK2 46/1 haplotype was documented in 69% of the study patients, including 25% in homozygous and 44% in heterozygous state. Driver mutation frequency in patients homozygous/heterozygous/nullizygous for the 46/1 haplotype was 78%/60%/56% JAK2, 10%/20%/18% type 1-like CALR, 3%/2%/5% type 2-like CALR, 4%/8%/7% MPL, and 6%/10%/14% triple-negative (P = .02). In univariate analysis, nullizygosity for the JAK2 46/1 haplotype was associated with inferior overall survival (HR 1.5, 95% CI 1.1-1.9), most pronounced in JAK2 (P <.001), as opposed to CALR/MPL mutated (P = .48) or triple-negative cases (P = .27). Multivariable analysis that included karyotype, driver mutational status and high-molecular risk mutations confirmed the independent prognostic contribution of nullizygosity for the 46/1 haplotype (P = .02; HR 1.4, 95% CI 1.1-1.8). Nullizygosity for 46/1 also remained significant in the context of the genetically-inspired GIPSS risk model (P = .04), but not in the context of the integrated genetics-clinical MIPSS70+ version 2.0 model (P = .4). Leukemia-free survival was not affected by the 46/1 haplotype (P = .6). The current study confirms the association of nullizygosity for the JAK2 GGCC (46/1) haplotype with inferior survival in JAK2-mutated PMF.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Lasho TL, Mudireddy M, et al. The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. Am J Hematol. 2018. PMID: 30516848. doi:10.1002/ajh.25349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。